Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 11/20 | 0.56 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23910706 | 1.00 | SIRT2 (0.56) | SIRT2ARSMN1; SMN2MCL1 | |
| SCHEMBL5909919 | 0.85 | SIRT2 (0.40) | SIRT2SMN1; SMN2 | |
| SCHEMBL23911049 | 0.84 | SIRT2 (0.43) | SIRT2SMN1; SMN2MCL1 | |
| SCHEMBL23911045 | 0.84 | SIRT2 (0.43) | SIRT2SMN1; SMN2MCL1 | |
| SCHEMBL23921841 | 0.84 | SIRT2 (0.63) | SIRT2AR | |
| SCHEMBL23910858 | 0.81 | SMN1; SMN2 (0.40) | SIRT2SMN1; SMN2MCL1 | |
| SCHEMBL23910855 | 0.81 | SMN1; SMN2 (0.40) | SIRT2SMN1; SMN2MCL1 | |
| SCHEMBL22616369 | 0.74 | AR (0.54) | ARSMN1; SMN2 | |
| SCHEMBL22616365 | 0.74 | AR (0.54) | ARSMN1; SMN2 | |
| SCHEMBL22617371 | 0.74 | AR (0.54) | ARSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | SIRT2 2369/4885AR 4173/4885SMN1; SMN2 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.